Of the liver that treat second " double amount to mark " target

Annual global liver ill field is extensive grand meeting -- American hepatic disease considers to learn annual meeting (AASLD) , ~11 will be held 4 days month at American san Francisco city on October 31 this year. 5 days in insecurity sessional in, the 8000 much famouser experts that come from 55 nations of world and area shared liver disease to research of domain forward position, cure suggests and treat new trend jointly. Bencihui is discussed still the focusing newest progress in basic research of liver ill domain and clinical practice, announce result of newest and clinical trial, how will attention study achievement applies at clinical practice. The conference opened plenary meeting report, wall newspaper communication and discuss, academic seminar, press conference, continue to teach the communication platform such as course. The theme that continues to teach course in current annual meeting is " the challenge that liver disease learns to be faced with " , curricular content includes: Mirror technique is in inside the remedial progress of the processing of complication of maximum pressure of pulse of disease of the application of liver ill domain, relevant courage and liver transplanting, door, third hepatitis and hepatitis B, inside mirror technique is in the processing of complication of maximum pressure of pulse of the application of liver ill division, door. Be aimed at the disease-resistant poison of second liver to treat is current the problem that domestic doctor, patient and its family member pay close attention to generally, reason the article makes progress newly to the clinical cure of second liver, basic research only and continue to teach content to undertake brief introducing partly. Double the disease-resistant poison that amounts to mark to treat a target to already got admissive 　 second liver extensively as disease-resistant poison is treated is the topic that gets attention fully in recent years, this conference is not exceptional also. The person that tell people reviewed disease of liver of a few international to learn an orgnaization, if disease of liver of AASLD, Europe learns (disease of liver of EASL) , Asia-Pacific learns (the guideline of APASL) , normative cure, need needs to the time illness that monitor makes progress and emphasize pausing medical opportune moment in emphasizing treating a process in disease-resistant poison repeatedly. The person that tell people the principal and short-term goal that approves treatment of chronic hepatitis B almost is " double amount to mark " , namely HBV DNA restrains as serological as HBeAg changeover. They still emphasized double those who amount to mark is important: Restrain HBV DNA to be able to improve patient disease process significantly, HBV DNA level and the happening with sclerotic liver closely related the risk; and electropositive to HBeAg (+ ) patient, the serological changeover of HBeAg is attached most importance to especially should. The process of HBeAg serological changeover is immunity the mark that cleared process and disease alleviate, at the same time adumbrative also liver cancer and liver cirrhosis produce a risk reduce. Accordingly, answer to the choice of disease-resistant bane content as far as possible the choice has strong virus to restrain hold HBeAg concurrently the medicaments with serological changeover high proportion. Gestation woman should choose 　 of medicaments of gravid B class this congress relatively before the disease-resistant poison that the conference pays close attention to special crowd more is treated, especially the disease-resistant poison of gestation woman is treated. Gestation fights virus to treat is clinical all the time the one catastrophe that go up is inscribed. The disease-resistant poisonous period of treatment of interferon is finite, but its treat serological changeover of a year of HBeAg to lead under 30% . And nucleotide (acerbity) analogue needs long-term treatment, divide for outside than the husband surely taller HBeAg serological changeover is led, other nucleotide (acerbity) analogue treats a year only make an appointment with 20%HBeAg electropositive patient to be able to realize HBeAg serological changeover. The Yo that this means much to accept disease-resistant poison to treat age the female needs to accept longer remedial ability to amount to mark, this appears likely also they produce gravid phenomenon during cure. On the other hand, if virus of liver of the second inside pregnant woman body is duplicate the volume is higher, if undertaking effective disease-resistant poison is treated, still put in the risk that Mu Ying spreads, endanger pregnant woman life between gestation even. Accordingly, courses of education of this congress continuity is special poisonous to the disease-resistant of gestation woman cure undertook discussion. Also reacting gestation disease-resistant poison is treated from this is to still need pressing the problem that solve. What announce this year is newest 2008 of edition " disease learns Asia-Pacific liver (APASL) chronic hepatitis B runs a guide " middle finger goes out: Poisonous to gravid woman disease-resistant cure should use remedy of gravid B class. All nucleotide that appear on the market in China (acerbity) in analogue, for be being decided than the husband is the medicaments of gravid B class that wins FDA approval exclusively at present, other nucleus (acerbity) analogue all is C class. (Class A: Animal experiment and clinical observation did not discover right fetal have damage. B class: Fact of animal solid test and verify does not have a harm to embryo, but clinical research fails to confirm or do not have data of clinical test and verify. C class: Confirm pair of embryo to have in animal experiment only send abnormal or reduce embryonic effect, but human lack studies the data confirms) . Accordingly, when undertaking to woman gestation disease-resistant poison is treated, should undertake risk and interest are evaluated, just can be when the interest is more than a risk only between gestation undertake disease-resistant poison is treated. International studies progress brings the disease that liver of new revelatory 　 second is internationalization, but up to now, the remedial effect that any medicaments or remedial method make all patient classics fights virus for a long time to cure is achieved and keep ideal hard. The pharmaceuticals with research and new development and remedial method are the important step that raises chronic hepatitis B to treat curative effect undoubtedly. Investigator people also have all sorts of research in ground of this domain advance wave upon wave. There are a lot of significant research gains on this conference. Korea Professor Dong Jin Suh undertook in Korea correct of a many center, head is replaced quite decide than the husband with favour for Ka Wei inchoate HBV-DNA restrains degree and virus of kinetic feature " 2407 research " . Study discovery is treated via 12 weeks, for be decided than the husband and favour for Ka Wei the precipitation below HBV-DNA of two groups of patients makes the same score likeness, the efficiency that the cleared rate, die out rate that gets infection cell and block sluggish virus produce the virus of two groups of patients is similar. Half-life of virus of dissociate of two groups of patients and infection cell half-life also similar. "2407 research " this one correct is replaced be decided than the husband and the favour comparative research for Ka Wei proved to replace decide than the husband with favour treating patient of chronic hepatitis B for Ka Wei inchoate restrain HBV duplicate ability comparatives basically, have powerful effect to control the capacity with second liver duplicate virus. This congress number is " 945 " the newest research that wall newspaper published Chinese Professor Ning Qin, for be in surely than the husband the generation that the middleman and guarantor of model of virus sex hepatitis with revulsive virus of small rat hepatitis protects Th1 cell factor and controls Th2 cell gene. The result shows, in the experiment outside body, for decide virus of hepatitis of small to MHV-3(rat than the husband) virus duplicates to did not affect; to replace make than the husband the generation of the cellular factor such as TNF- α , IL-12 adds surely. In the experiment inside body, for the generation that can stimulate γ of cellular factor IFN- surely than the husband, restrain the generation of cellular factor IL-4, at the same time clear improvement liver organizes fiber to change, raise the surviving rate of small rat. This experiment shows for decide virus of pair of the liver that be not second to do not have direct inhibition than the husband, this and for decide than the husband clinical before study consistent; is replaced decide independent Yu Kang to arise and control Th2 cell gene what raise Th1 cell factor besides virus than the husband, clew is replaced have immune adjustment effect surely than the husband. Clinical research seeks remedy obtain achieve " double amount to mark " way 　 replaces Nuofuwei is to be in what the European Union approves to be used at treating an adult recently acting countervail sex is chronic the new-style nucleotide of hepatitis B (acerbity) analogue, have not appear on the market in China at present. On this congress, what treat two research of chronic hepatitis B about replacing Nuo blessing Wei is newest 96 weeks of research caused wide attention as a result. These two research are to apply TDF and ADV to be aimed at HBeAg positive (103 research) with HBeAg negative (102 research) acting countervail sex is treated first the Ⅲ of chronic hepatitis B period register an experiment to shine on bed. "103 research " as a result indication course is treated 96 weeks, HBeA electropositive patient appears in the patient that has 6% 96 weeks HBsAg turns shade, the PCR that 84% patients can achieve HBV-DNA detects the patient of group of Wei of the blessing that replace Nuo of electronegative;27% appears HBeAg is serological changeover, ; of occurrence HBeAg serological changeover has the 22% patients that in 48 weeks of You Ade Fu Wei changes into Wei of the blessing that replace Nuo 2 patients confirm flesh anhydride is elevatory, a patient needs to change dosage. "102 research " in the PCR that HBeAg electronegative patient can achieve HBV-DNA in 96 weeks of 89% patients detects electronegative; shares the patient of 7% to interrupt cure. The place on put together is narrated, double amount to mark -- HBV-DNA is restrained and HBeAg serological changeover, become disease-resistant poison to treat a target to already got be admissived extensively, defy so the choice of virus medicaments should as far as possible the choice can be offerred at the same time strong virus is restrained and tall HBeAg is serological the disease-resistant poison cure of the woman of medicaments; gestation of changeover should choose medicaments of gravid B class. New clinical research result and data brought new revelation to us: For decide than the husband with favour for Ka Wei head correct studies result report shows two medicaments are had coequal the virus inhibition; of powerful effect is replaced have effect of the mix on immunity surely than the husband, replace be in surely than the husband the virus sex hepatitis with revulsive virus of small rat hepatitis. (the exercitation edits: Plum apricot)